John Wrangle to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications John Wrangle has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.665
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.463
-
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2015 Jan 01; 6(1):56-70.
Score: 0.092
-
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011 Dec; 1(7):598-607.
Score: 0.074
-
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021 09; 16(9):1559-1569.
Score: 0.035